National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, Roundtable on Genomics and Precision Health, National Cancer Policy Fo
Where people live can affect their health because of location-specific exposure to chemicals and toxicants, lifestyle, diet, immune function development, and social and historical determinants of health. A better understanding of the connections bet...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, Board on Health Sciences Policy, Roundtable on Genomics and Precision Hea
The National Academies Roundtable on Genomics and Precision Health, in collaboration with the National Cancer Policy Forum, hosted a public workshop that examined how genomic data are used in health care, outside of the traditional settings for clin...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Forum on Drug Discovery, Development, and Translation, Carolyn S...
On March 24, 2020, a 1-day public workshop titled The Role of Digital Health Technologies in Drug Development was convened by the National Academies of Sciences, Engineering, and Medicine. This workshop builds on prior efforts to explore how virtual...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, National Cancer Policy Fo
The workshop participants examine the current state of clinical trial data sharing and reuse and consider ways in which policy, technology, incentives, and governance could be leveraged to further encourage and enhance data sharing--...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Sarah H. Beachy, Joe Alper, Siobhan Addie, Meredith Hackmann...
Consumer genomics, encompassing both direct-to-consumer applications (i.e., genetic testing that is accessed by a consumer directly from a commercial company apart from a health care provider) and consumer-driven genetic testing (i.e., genetic testi...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, National Cancer Policy Fo
Sharing knowledge is what drives scientific progress - each new advance or innovation in biomedical research builds on previous observations. However, for experimental findings to be broadly accepted as credible by the scientific community, they mus...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Sarah H. Beachy, Joe Alper, Siobhan Addie
Genomic medicine is defined as the routine use of genomic information about an individual as part of his or her clinical care as well as the health outcomes and policy implications of that clinical use. It is one approach that has the potential to i...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Sarah Beachy, Theresa Wizemann, Meredith Hackmann, Siobhan Addie...
Genomic applications are being integrated into a broad range of clinical and research activities at health care systems across the United States. This trend can be attributed to a variety of factors, including the declining cost of genome sequencing...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Roundtable on Genomics and Precision Health, Forum on Drug Discovery, Development, and Translation, Sarah H. B...
Those involved in the drug development process face challenges of efficiency and overall sustainability due in part to high research costs, lengthy development timelines, and late-stage drug failures. Novel clinical trial designs that enroll partici...Lasīt vairāk
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, Roundtable on Genomics and Precision Health, Sarah H. B...
The process of discovering and developing a new drug or therapy is extremely costly and time consuming, and recently, it has been estimated that the creation of a new medicine costs on average more than 2 billion and takes 10 years to reach patient...Lasīt vairāk
